866-997-4948(US-Canada Toll Free)

Chondrosarcoma - Pipeline Review, H1 2017

Published By :

Global Markets Direct

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 165 Pages

Chondrosarcoma - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chondrosarcoma - Pipeline Review, H1 2017, provides an overview of the Chondrosarcoma (Oncology) pipeline landscape.

Chondrosarcoma is a malignant cancer whose tumor cells produce a pure hyaline cartilage that results in abnormal bone and/or cartilage growth. Signs and symptoms include pain in the affected area that may worsen at night or during physical activity, swelling in the painful area, a lump or mass, enlargement of an existing growth, limping, difficulty moving the affected limb, changes in urination. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chondrosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chondrosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chondrosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 7, 3 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Chondrosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chondrosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Chondrosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chondrosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chondrosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chondrosarcoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chondrosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chondrosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Chondrosarcoma - Overview 6
Chondrosarcoma - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Chondrosarcoma - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Chondrosarcoma - Companies Involved in Therapeutics Development 20
Agios Pharmaceuticals Inc 20
Celgene Corp 20
CytRx Corp 21
Daiichi Sankyo Company Ltd 21
EpiZyme Inc 22
Horizon Pharma Plc 22
Karyopharm Therapeutics Inc 23
Merck & Co Inc 23
Novartis AG 24
Pfizer Inc 24
Chondrosarcoma - Drug Profiles 25
aldoxorubicin hydrochloride - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
axitinib - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
DS-1001 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
enasidenib mesylate - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
galarmin - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
interferon gamma-1b - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
ivosidenib - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
ligerin - Drug Profile 67
Product Description 67
Mechanism Of Action 67
R&D Progress 67
pazopanib hydrochloride - Drug Profile 68
Product Description 68
Mechanism Of Action 68
R&D Progress 68
pembrolizumab - Drug Profile 76
R&D Progress 77
selinexor - Drug Profile 128
Product Description 128
Mechanism Of Action 128
R&D Progress 128
sirolimus - Drug Profile 149
Product Description 149
Mechanism Of Action 149
R&D Progress 149
tazemetostat - Drug Profile 151
Product Description 151
Mechanism Of Action 151
R&D Progress 151
Chondrosarcoma - Dormant Projects 160
Chondrosarcoma - Discontinued Products 161
Chondrosarcoma - Product Development Milestones 162
Featured News & Press Releases 162
Nov 18, 2016: Agios Announces Phase 1 Data from Dose Expansion Cohorts of AG-120 in Patients with IDH1 Mutant Positive Glioma and Chondrosarcoma 162
Appendix 164
Methodology 164
Coverage 164
Secondary Research 164
Primary Research 164
Expert Panel Validation 164
Contact Us 164
Disclaimer 165

List of Tables
Number of Products under Development for Chondrosarcoma, H1 2017 7
Number of Products under Development by Companies, H1 2017 8
Number of Products under Development by Universities/Institutes, H1 2017 9
Products under Development by Companies, H1 2017 10
Products under Development by Universities/Institutes, H1 2017 11
Number of Products by Stage and Target, H1 2017 13
Number of Products by Stage and Mechanism of Action, H1 2017 15
Number of Products by Stage and Route of Administration, H1 2017 17
Number of Products by Stage and Molecule Type, H1 2017 19
Chondrosarcoma - Pipeline by Agios Pharmaceuticals Inc, H1 2017 20
Chondrosarcoma - Pipeline by Celgene Corp, H1 2017 20
Chondrosarcoma - Pipeline by CytRx Corp, H1 2017 21
Chondrosarcoma - Pipeline by Daiichi Sankyo Company Ltd, H1 2017 21
Chondrosarcoma - Pipeline by EpiZyme Inc, H1 2017 22
Chondrosarcoma - Pipeline by Horizon Pharma Plc, H1 2017 22
Chondrosarcoma - Pipeline by Karyopharm Therapeutics Inc, H1 2017 23
Chondrosarcoma - Pipeline by Merck & Co Inc, H1 2017 23
Chondrosarcoma - Pipeline by Novartis AG, H1 2017 24
Chondrosarcoma - Pipeline by Pfizer Inc, H1 2017 24
Chondrosarcoma - Dormant Projects, H1 2017 160
Chondrosarcoma - Discontinued Products, H1 2017 161

List of Figures
Number of Products under Development for Chondrosarcoma, H1 2017 7
Number of Products under Development by Companies, H1 2017 8
Number of Products by Top 10 Targets, H1 2017 12
Number of Products by Stage and Top 10 Targets, H1 2017 12
Number of Products by Top 10 Mechanism of Actions, H1 2017 14
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017 14
Number of Products by Routes of Administration, H1 2017 16
Number of Products by Stage and Routes of Administration, H1 2017 16
Number of Products by Molecule Types, H1 2017 18
Number of Products by Stage and Molecule Types, H1 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *